Drugs / PRV-6527
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03854305 | Mar 2018 → Aug 2019 | Crohn disease | Provention Bio, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRV-6527 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03854305 ↗ |
| Known as | JNJ-40346527 | “oral PRV-6527 (JNJ-40346527), an Inhibitor of CSF-1 Receptor” NCT03854305 ↗ |
| Action | Inhibit | “an Inhibitor of CSF-1 Receptor” NCT03854305 ↗ |
| Route | Oral | “Oral administration, 2X daily for 12 weeks” NCT03854305 ↗ |